[Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system].
Platelet functional parameters (platelet aggregation, blood circulating reversibly and irreversibly aggregated platelet complexes, thromboxane B2, 6-keto-PGF1 alpha) were examined in unstable angina treated with aspirin in a daily dose of 320 mg in relation to the outcome of the disease: Group 1, stabilization and Group 2, evolving myocardial infarction. Differences were found in the baseline platelet functional parameters between the groups. The findings suggest that platelet functional parameters show a varying response to aspirin depending on the outcome of the disease. Despite the effective inhibition of thromboxane A2 synthesis, aspirin was found to fail to prevent enhanced platelet aggregatory activity in case of myocardial infarction developed during the therapy.
Shalaev
S V
SV
D000328:Adult; D000789:Angina, Unstable / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D011464:Epoprostenol / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000209:etiology; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D013931:Thromboxanes / Q000502:physiology*
D013931:Thromboxanes; D011464:Epoprostenol; D001241:Aspirin
Razvitie infarkta miokarda pri lechennoĭ aspirinom nestabil'noĭ stenokardii. Povtornie issledovaniia agregatsii trombotsitov i tromboksan-prostatsiklinovoĭ sistemy.